ATE254457T1 - Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil - Google Patents

Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil

Info

Publication number
ATE254457T1
ATE254457T1 AT98932526T AT98932526T ATE254457T1 AT E254457 T1 ATE254457 T1 AT E254457T1 AT 98932526 T AT98932526 T AT 98932526T AT 98932526 T AT98932526 T AT 98932526T AT E254457 T1 ATE254457 T1 AT E254457T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
composition containing
aqueous liquid
liquid pharmaceutical
main ingredient
Prior art date
Application number
AT98932526T
Other languages
English (en)
Inventor
Shinichi Yasueda
Tadashi Terai
Takahiro Ogawa
Yoshinori Ii
Original Assignee
Ono Pharmaceutical Co
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co, Senju Pharma Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE254457T1 publication Critical patent/ATE254457T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98932526T 1997-07-23 1998-07-15 Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil ATE254457T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP19677197 1997-07-23
PCT/JP1998/003172 WO1999004790A1 (en) 1997-07-23 1998-07-15 Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative

Publications (1)

Publication Number Publication Date
ATE254457T1 true ATE254457T1 (de) 2003-12-15

Family

ID=16363363

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98932526T ATE254457T1 (de) 1997-07-23 1998-07-15 Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil

Country Status (9)

Country Link
US (1) US6274609B1 (de)
EP (1) EP0996442B1 (de)
KR (1) KR20010022113A (de)
AT (1) ATE254457T1 (de)
CA (1) CA2296562A1 (de)
DE (1) DE69819900T2 (de)
ES (1) ES2206956T3 (de)
TW (1) TW546151B (de)
WO (1) WO1999004790A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990021841A (ko) * 1995-05-23 1999-03-25 페터 제이 기딩스 의약에 향미 부형제를 첨가하여 제조된 약학적 조성물
KR100381834B1 (ko) * 2000-05-20 2003-04-26 이상득 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법
ES2261671T3 (es) * 2001-03-26 2006-11-16 Novartis Ag Mezcla farmaceutica que incluye una estaurosporina poco soluble en agua, un surfactante y un polimero soluble en agua.
EP1586316B1 (de) 2003-01-21 2008-04-30 Senju Pharmaceutical Co., Ltd. Wässrige flüssige zubereitung mit 2-amino-3-(4-bromobenzoyl)phenylessigsäure
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
KR100715355B1 (ko) 2005-09-30 2007-05-07 주식회사유한양행 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
KR101739815B1 (ko) * 2010-12-01 2017-05-26 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물
KR101739816B1 (ko) * 2010-12-01 2017-05-25 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물 또는 주사용 건조 분말
CN102178647B (zh) * 2011-04-28 2012-09-12 重庆圣华曦药物研究开发有限公司 普仑司特注射制剂
KR102478553B1 (ko) * 2018-02-28 2022-12-16 한림제약(주) 벤조피란 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 용액 형태의 점안제
CN121532170A (zh) * 2023-07-18 2026-02-13 三亚制药株式会社 含普仑司特的药物组合物的制备方法以及通过所述制备方法制备的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0641569A4 (de) 1992-03-12 1997-01-29 Ono Pharmaceutical Co Antipruritisches agens.
JP3814833B2 (ja) 1994-09-02 2006-08-30 小野薬品工業株式会社 プランルカストおよびポリビニルピロリドンまたはβ−シクロデキストリンからなる製剤
DK0834314T3 (da) 1995-06-12 2003-02-24 Ono Pharmaceutical Co Granuler der indeholder pranlukast, fremgangsmåde til fremstilling af granulerne, og fremgangsmåde til reduktion af pranlukasts klæbeevne
JP3665166B2 (ja) * 1996-07-24 2005-06-29 東京応化工業株式会社 化学増幅型レジスト組成物及びそれに用いる酸発生剤

Also Published As

Publication number Publication date
WO1999004790A1 (en) 1999-02-04
TW546151B (en) 2003-08-11
CA2296562A1 (en) 1999-02-04
DE69819900D1 (de) 2003-12-24
DE69819900T2 (de) 2004-04-15
KR20010022113A (ko) 2001-03-15
ES2206956T3 (es) 2004-05-16
EP0996442B1 (de) 2003-11-19
EP0996442A1 (de) 2000-05-03
US6274609B1 (en) 2001-08-14

Similar Documents

Publication Publication Date Title
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
ATE327977T1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
ES2124793T3 (es) Derivados de rapamicina alquilados en o y su uso, particularmente como inmunosupresores.
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
BR9807383A (pt) Formulação farmacêutica que compreende amoxicilina e clavulanato
ATE254457T1 (de) Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil
AR030245A1 (es) Composiciones de gel que contienen metronidazol
NL990030I1 (nl) Derivaten en analogen van 2-deoxy-2,3-didehydro-N-acetylneuraminezuur en het gebruik ervan als antivirale middelen.
BR0111639A (pt) Uso de uma molécula de ácido oligodeoxinucléico, e composição farmacêutica contendo a mesma
BR9916132B1 (pt) composiÇÕes e utilizaÇço das mesmas.
NO326660B1 (no) Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene
FI962494L (fi) 5-(2-imidatsolinyyliamino)bentsimidatsolijohdannaisia, niiden valmistus ja niiden käyttö alpha-2-adrenoseptoriagonisteina
TR200200795T2 (tr) 5-HT1B antagonistleri olarak piperazin türevleri
ATE286057T1 (de) Pharmazeutische zubereitungen enthaltend clavulansäure
BRPI0215331B8 (pt) composições aquosas contendo metronidazol
CO4290432A1 (es) Nuevos derivados de pirazinacarboxamida, su preparacion y su utilizacion en medicamentos.
DE50004443D1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
BR0110290A (pt) Preparação lìquida estabilizada
EA200200545A1 (ru) Онколитические комбинации для лечения рака
IT1302264B1 (it) Derivati a struttura n-acil vanillinamidica in grado di attivare irecettori periferici dei cannabinoidi
ES2180319T3 (es) Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos.
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
BR0108075B1 (pt) composição amaciante de tecido, e, uso de uma dispersão aquosa.
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
CO5170467A1 (es) Capsulas de eter de celulosa libres de turbiedad y proceso para hacer las mismas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties